MANCHESTER, Md.–(BUSINESS WIRE)– “Today, KBG Foundation announces its partnership with Boston-based FDNA to accelerate precision medicine and grow the number of confirmed KBG global cases. Clinicians working with the KBG Foundation helped to train FDNA’s facial analysis technology, Face2Gene, to better recognize the clinical signs of KBG Syndrome in patients. The results from this work are now being made available to experts globally to better diagnose and treat patients suffering from KBG.”
Fetal Fentanyl Syndrome: Unveiling a New Syndrome Linked to Fentanyl Use During Pregnancy
Dr. Karen Gripp, MD, Chief of the Division of Medical Genetics at Nemours Children’s Health in Wilmington, has been at the forefront of groundbreaking research into what is now termed Fetal Fentanyl Syndrome—a novel condition observed in children exposed to fentanyl in utero in the context of a maternal opioid use disorder. This emerging syndrome […]